Rubric Capital Management LP Boosts Stake in scPharmaceuticals Inc. (NASDAQ:SCPH)

Rubric Capital Management LP increased its position in scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) by 35.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,775,000 shares of the company's stock after acquiring an additional 1,250,000 shares during the period. Rubric Capital Management LP owned about 9.54% of scPharmaceuticals worth $21,774,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. BNP Paribas Financial Markets grew its holdings in scPharmaceuticals by 116.9% during the third quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company's stock valued at $26,000 after purchasing an additional 3,101 shares during the period. The Manufacturers Life Insurance Company bought a new stake in scPharmaceuticals during the third quarter valued at about $57,000. Virtu Financial LLC bought a new position in shares of scPharmaceuticals in the first quarter worth about $90,000. Balanced Rock Investment Advisors LLC boosted its stake in shares of scPharmaceuticals by 10.3% in the second quarter. Balanced Rock Investment Advisors LLC now owns 63,130 shares of the company's stock worth $275,000 after acquiring an additional 5,882 shares during the period. Finally, Assenagon Asset Management S.A. boosted its stake in shares of scPharmaceuticals by 266.7% in the second quarter. Assenagon Asset Management S.A. now owns 72,692 shares of the company's stock worth $316,000 after acquiring an additional 52,870 shares during the period. Institutional investors own 89.52% of the company's stock.

scPharmaceuticals Price Performance

Shares of NASDAQ SCPH traded up $0.13 during mid-day trading on Wednesday, reaching $3.73. The company's stock had a trading volume of 314,826 shares, compared to its average volume of 274,891. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89. The firm has a market capitalization of $186.65 million, a PE ratio of -1.89 and a beta of 0.15. scPharmaceuticals Inc. has a 52 week low of $3.08 and a 52 week high of $6.71. The stock has a fifty day moving average of $4.20 and a two-hundred day moving average of $4.42.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price objective on shares of scPharmaceuticals in a research note on Thursday, November 14th. Craig Hallum dropped their price objective on scPharmaceuticals from $16.00 to $12.00 and set a "buy" rating for the company in a research note on Thursday, November 14th.

scPharmaceuticals Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.